<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01249859</url>
  </required_header>
  <id_info>
    <org_study_id>ADCI 001</org_study_id>
    <nct_id>NCT01249859</nct_id>
  </id_info>
  <brief_title>Prognosis of Signet Ring Cells in Upper Digestive Neoplasms</brief_title>
  <acronym>ADCI001</acronym>
  <official_title>Has the Quota of Signet Ring Cells an Influence on Prognosis and Treatment Strategy in the Upper GI Tract Adenocarcinomas?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Lille</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Lille</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background â€¢ A major increase in incidence of signet ring cell adenocarcinomas (ADCI) of the&#xD;
      upper digestive tract in western countries&#xD;
&#xD;
        -  Discordant results in the literature concerning the prognosis value of the presence of&#xD;
           signet ring cells.&#xD;
&#xD;
        -  Preliminary data suggesting (i) an advanced stage at time of diagnosis, (ii) more often&#xD;
           in the form of carcinose, (iii) a more pejorative prognosis, (iv) a recurrence more&#xD;
           frequent, more quickly, and more often in the form of peritoneal carcinose, (v) a chemo&#xD;
           resistance (vi) the need for a specific therapeutic strategy compared to non-signet ring&#xD;
           cell adenocarcinomas.&#xD;
&#xD;
      Primary objective To test the hypothesis that 5-year survival rate is significantly lower in&#xD;
      the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the&#xD;
      upper digestive tract&#xD;
&#xD;
      Secondary objectives&#xD;
&#xD;
        -  Impact of neoadjuvant CT on overall survival&#xD;
&#xD;
        -  Impact and differential diagnostic value of linitis&#xD;
&#xD;
        -  R0 resection rates&#xD;
&#xD;
        -  3 years recurrence free survival&#xD;
&#xD;
        -  Overall 3 years survival&#xD;
&#xD;
        -  Prognostic factors&#xD;
&#xD;
        -  Prognostic value of the presence of a minority quota of signet ring cell&#xD;
&#xD;
        -  Objective response rate after medical treatment (chemotherapy, radiochemotherapy) in&#xD;
           non-resected patients&#xD;
&#xD;
        -  Tolerance of (radio) chemotherapy for ADCI&#xD;
&#xD;
      Methodology Intention to treat retrospective case-control multicentric study A pairing on&#xD;
      demographic criteria (age, sex, ASA score, center) and tumor criteria (TNM stage) will be&#xD;
      done to ensure comparability in case control study groups.&#xD;
&#xD;
      Inclusion criteria All consecutive patients taken care of, for a proven histologically&#xD;
      adenocarcinoma (ADCI and ADNCI) of the esophagus, the esogastric junction, or the stomach, in&#xD;
      surgical or medical oncology investigator centers, will be saved in a given database.&#xD;
&#xD;
      For whom the first consultation took place between January 1997 and January 2010&#xD;
&#xD;
      Exclusion criteria Histological type other than adenocarcinoma Other localization than&#xD;
      esogastric junction, esophagus or stomach&#xD;
&#xD;
      Planned study period The data will be collected over a period from January 1997 to January&#xD;
      2010.&#xD;
&#xD;
      The objective is to complete the data collection for summer 2010.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      stomach cancer signet ring cell carcinoma prognosis chemotherapy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To test the hypothesis that 5-year survival rate is significantly lower in the signet ring cells (SRC) adenocarcinoma when compared to non-SRC adenocarcinoma in the upper digestive tract</measure>
    <time_frame>participants are followed until death or time point at 31 september 2010</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>3 year recurrence free survival</measure>
    <time_frame>participants are followed until recurrence or time point at 31 september 2010</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall 3 year survival according to tumor stage, node invasion, and tumor localization</measure>
    <time_frame>participants are followed until death or time point at 31 september 2010</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">2500</enrollment>
  <condition>Signet Ring Cell Carcinoma</condition>
  <condition>Stomach Disease</condition>
  <condition>Oesophagus</condition>
  <condition>Prognostic</condition>
  <condition>Case-control Study</condition>
  <arm_group>
    <arm_group_label>Signet ring cell carcinoma</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>non signet ring cell adenocarcinoma</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Intention to treat retrospective case control multicentric study, Patients will be divided&#xD;
        into two groups (ADCI or ADNCI) depending on the presence or not of signet ring cells on&#xD;
        definitive histologic analysis Another analysis based on chemo administration or not will&#xD;
        be provided A pairing on demographic criteria (age, sex, ASA score, center, TNM stage and&#xD;
        will be done to ensure comparability in case control study groups.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All consecutive patients taken care of, for a proven histologically adenocarcinoma&#xD;
             (ADCI and ADNCI) of the esophagus, the esogastric junction, or the stomach, in&#xD;
             surgical or medical oncology investigator centers, will be saved in a given database.&#xD;
&#xD;
          -  For whom the first consultation took place between January 1997 and January 2010&#xD;
&#xD;
          -  As they benefit from a medical and/or surgical support (primitive cancer being or not&#xD;
             resected), whatever the metastatic or the recurrence situation was.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histological type other than adenocarcinoma&#xD;
&#xD;
          -  Other localization than esogastric junction, esophagus or stomach&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>95 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>christophe mariette, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>CHU lille</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital of Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2014</verification_date>
  <study_first_submitted>October 26, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <last_update_submitted>December 8, 2014</last_update_submitted>
  <last_update_submitted_qc>December 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stomach disease</keyword>
  <keyword>signet ring cell carcinoma</keyword>
  <keyword>chemotherapy</keyword>
  <keyword>Prognostic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Signet Ring Cell</mesh_term>
    <mesh_term>Stomach Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

